Setting the Global Standard in Organ-on-Chip Innovation

Anivance AI (久浪智醫) is Taiwan's leading organ-on-chip company, specializing in AI-driven microphysiological systems (MPS) for regulatory-aligned drug development. The team was formed in 2021 by Dr. Guan-Yu Chen and officially incorporated as Anivance AI in June 2024. The company has rapidly emerged as a global innovator in

The company's flagship lung-on-chip platform simulates the human air-liquid interface and respiratory exposure environment, enabling high-fidelity inhalation toxicology testing without animal models. This technology was validated through selection into the FNIH NAMs (New Approach Methodologies) global pilot program — a landmark achievement for organ-on-chip technology from Taiwan.

Beyond inhalation toxicology, Anivance AI's platform supports multi-organ modeling including liver, CNS, immune system, and tumor microenvironment, with integrated AI analytics for high-throughput phenotypic analysis and predictive modeling. The platform is designed for IND-enabling preclinical studies and regulatory submissions to the FDA and EMA.